Navigation Links
Thrombolytic in Medical News

Portable CT increases chance of stroke survival and recovery

... to increase the number of patients to whom thrombolytic therapy can be administered," said the study's ... in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves ... number of stroke patients able to be treated with thrombolytic therapy within the three-hour window. ...

New therapy effectively treats deep vein thrombosis

... injecting or lacing the clot with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis ... years of their initial DVT. Treatments with thrombolytic (clot-dissolving) therapy could potentially ... to develop a safe, effective and affordable thrombolytic treatment regimen for DVT. Twenty patients ...

Stroke therapy window might be extended past nine hours for some

... between the lesions suggests that a patient might still benefit from thrombolytic therapy." In the study, most patients with blockage in a proximal ... suggest a need for a clinical trial to measure the effectiveness of thrombolytic therapy more than nine hours after the onset of an ischemic stroke." ...

New blood clot guidelines for pregnant women

... of the American College of Chest Physicians (ACCP), Antithrombotic and thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition ... variety of options for care in special patient groups." Antithrombotic and thrombolytic therapies are used to prevent and treat thrombosis or blood clotting that ...

Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group

... be used to a lesser extent in the treatment of upper limb DVT and peripheral artery occlusion. PMT combines the direct delivery of "clot-busting" thrombolytic drugs with mechanical clot disruption, and is posited to be safer, more effective, and more efficient than CDT alone due to the lower dose of ...

Rush University Medical Center orthopaedic experts examine overhead

... rare, neurovascular disorders cause significant damage and recovery may be difficult. Successful non-operative treatment methods include rest and thrombolytic and anticoagulation injections used to diffuse blood clots. However, thirty percent of throwers will not respond to conservative measures and will ...

Journal Chest: April news briefs

... for deep vein thrombosis (DVT) or blood clots, a new study suggests that patients who undergo podiatric surgery may have a relatively low risk for thrombolytic events. In a 5-year retrospective analysis, researchers from Kaiser Permanente Center for Health Research reviewed the charts of 7,264 patients who ...

Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression

... of patent applications for the technology. Moreover, this is the second molecule that IMTECH has under license with Nostrum, the first being a novel thrombolytic clot-buster protein known as SMRX11. While SMRX11 was the first patented recombinant DNA based biopharmaceutical molecule licensed to a foreign ...

January 2009 Mayo Clinic Women's HealthSource Highlights Stroke Symptoms, Personal Health Records and Volunteering

... or unusual symptoms that seem to get better or that aren't painful." In years past, treatment options for stroke were limited. That's changed. thrombolytic drugs, also known as clot busters, are used to treat ischemic stroke and reduce the risk of permanent brain damage that can cause paralysis or ...

Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients

... work as hoped in a trial, but they haven't given up on the idea. "In specific situations, those patients with pulmonary embolism, use of this thrombolytic agent can stabilize the patient and help the patient survive," said Dr. Bernd W. Böttiger, professor and head of the department of ...
Thrombolytic in Medical Technology

Portable CT Increases Chance of Stroke Survival and Recovery

... to increase the number of patients to whom thrombolytic therapy can be administered," said the study's ... in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves ... number of stroke patients able to be treated with thrombolytic therapy within the three-hour window. ...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

... completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix ... animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which ...

Is PCI Safe, Effective After Clot-Busters for Heart Attack?

... PCI after treating patients with clot-busting drugs -- also known as thrombolytic or fibrinolytic agents -- offered no benefit and might even be harmful. Since then, however, thrombolytic medications have changed, stents are routinely used, and interventional ...

ImaRx Therapeutics Transitions Business Strategy

... the Company's first commercially available FDA approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ... formularies at approximately 700 acute care hospitals. Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ...

Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion

... 3 SONOMA study provided further evidence that alfimeprase is an active thrombolytic which has the potential to dissolve clots quickly and rapidly restore ... that increasing the concentration can result in marked improvement in thrombolytic activity. Accordingly, we are resuming development of alfimeprase in CO to ...

Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

... of CDT procedures. There were no reported bleeding complications related to the Trellis device in acute follow up and the dosage of thrombolytic drugs such as t-PA was reduced by 30% with use of the Trellis device compared to CDT. "Profound changes in the treatment paradigm for DVT are ...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

... programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; ...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

... as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more ...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

... 600,000 new attacks and 320,000 recurrent attacks. After an acute myocardial infarction, early and successful myocardial reperfusion with the use of thrombolytic therapy such as tissue plasminogen activator (tPA) or primary percutaneous coronary intervention (PCI) is the most effective strategy for reducing ...

CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors

... patients up to 24 hours after symptom onset and another which adds NeuroFlo treatment to the current standard of care -- intravenous delivery of the thrombolytic drug, t-PA. CoAxia, Inc. is a venture-backed, privately held, development-stage company focused on providing perfusion augmentation therapies that ...

More>>

Thrombolytic in Medical Products

HYDROLYSER Thrombectomy Catheter 7F Dual Lumen

Description:... provides an efficient, patient-friendly alternative to surgery and thrombolytic therapy. Compatible with your existing contrast power injector. ... a 360 vortex that fragments and aspirates thrombus into the exhaust lumen. thrombolytic material is discharged through the exhaust lumen into a collection ....
Company:Cordis Corporation

HYDROLYSER Thrombectomy Catheter 6F Triple Lumen

Description:... provides an efficient, patient-friendly alternative to surgery and thrombolytic therapy. Compatible with your existing contrast power injector. ... 360 vortex that fragments and aspirates thrombus into the exhaust lumen. thrombolytic material is discharged through the exhaust lumen into a collection ....
Company:Cordis Corporation

Vascular ClearWay Irrigating PTFE Balloon Catheter

Features:... More efficient thrombus removal Precision delivery of thrombolytic Soft, non-compliant PTFE balloon Low pressure (2-3 ATM) atraumatic balloon expansion Central RO marker aids in placement ...
Company:Atrium Medical Corporation
Thrombolytic in Medical Dictionary

Thrombolytic therapy

... thrombolytic therapy Definition: thrombolytic therapy involves the use of drugs that break up ... treating acute myocardial infarction s than thrombolytic therapy . ...

Clot

... of Clot -dissolving medication Clot -dissolving medication: See: thrombolytic agent. Search All of MedicineNet For: search help ... Alternate Names : ... (known as thombolytics) Percentage of people with a heart attack given thrombolytic treatment within 30 minutes of arrival at hospital : ... A blood ...

ALS

... factors. Receive our free newsletter or manage your subscriptions ... ALS ( Amyotrophic Lateral Sclerosis ) Alstrom Syndrome ALT Alteplase ( thrombolytic Therapy ( Tissue Plasminogen Activator - TPA)) Altered Mental Status ( Unconsciousness - First Aid) ... ( ALS )(´´mtrf´ik, ...

Amyotrophic lateral sclerosis

... BASIC APPLICATIONS"Prolonged Neutral Baths, 1-3 hours daily; massage. ALS ( Amyotrophic Lateral Sclerosis ) Alstrom Syndrome ALT Alteplase ( thrombolytic Therapy ( Tissue Plasminogen Activator - TPA)) Altered Mental Status ( Unconsciousness - First Aid) ... ALS ( amyotrophic lateral sclerosis ...

Cardiopulmonary Resuscitation

... first aid in the form of cardiopulmonary resuscitation (CPR), an emergency balloon angioplasty , or the administration of beta -blockers and thrombolytic drugs ( clot -dissolving drugs), ... ...

Deep venous thrombosis

... the risk of complications such as deep venous thrombosis , stroke , and heart attack . Fountain infusion system and catheter System delivers thrombolytic agents to dissolve blood clots , indicated for treatment of occluded peripheral arteries and hemo dialysis graft s, and deep venous ...

Heart Attack

... of heart attack and stroke . It is also being studied in the treatment of cancer . Activase belongs to the family of drugs called systemic thrombolytic agents. Although the dangers of anorexia are more apparent because of a person's substantial weight loss or very low weight, bulimia can, in ...

Heart bypass surgery

... blood flow to the heart after cardiac catheterization , heart bypass surgery , angioplasty , atherectomy, or medication to dissolve a clot ( thrombolytic therapy ). Unlike conventional open- heart bypass surgery , which requires a large incision , MIDCAB employs a tiny, 6-10 cm "keyhole" incision ...

Stroke

... of heart attack and stroke . It is also being studied in the treatment of cancer . Activase belongs to the family of drugs called systemic thrombolytic agents. In case you need more motivation to lose weight, here is a partial list of the medical problems whose frequency is increased by obesity ...

Temper tantrums

... Tantrums Temperature - Aging Changes ( Aging Changes in Vital Signs ) Temperature - Normal (Body Temperature Normals) Tenecteplase ( thrombolytic Therapy ( Tissue Plasminogen Activator - TPA)) ... Screaming or temper tantrums when left with others Insistence on sleeping with parents in ...

More>>

Thrombolytic in Biological News

Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf

... with thalassemia major and thalassemia intermediate found that the rate of thrombolytic events was 1.75 percent. Surgical technique has played a role in ... prophylactic anticoagulants any time thalassemic patients are exposed to thrombolytic risk factors such as surgery, prolonged immobilization or pregnancy. Oral ...

New compound reduces stroke damage

... thrombus within the blood vessel. Because of the lack of available stroke treatments, neuroprotective agents have also generated as much interest as thrombolytic therapies. The immunosuppressive drug FK506 (also known as Tacrolimus or Prograf®) is often administered to patients receiving transplants to ...
Thrombolytic in Biological Technology

ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent

... look forward to moving this unique thrombolytic agent quickly into the clinic and toward ... the development of THR-100 as a novel thrombolytic agent. Bharat Biotech has significant expertise ... a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including ...

ThromboGenics N.V. - Business Update

... after the stroke event, and with potentially fewer side-effects than other thrombolytic agents. The MITI IV study is placebo controlled and is evaluating the ... is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics ...

ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase

... Microbix to Acquire Commercialized thrombolytic and Related Assets for $17 Million ... suffering from acute ischemic stroke. About Urokinase Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ...

ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase

... property rights, now resides unencumbered with ImaRx. Urokinase is a thrombolytic drug, formerly marketed under the brand name Abbokinase(R) and recently ... formularies at approximately 700 acute care hospitals. Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ...

ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke

... blood clots such as those that cause acute stroke. It is a direct-acting thrombolytic agent that has the potential to restore blood flow efficiently within an ... is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics ...

ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007

... of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006. Net loss per ... of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006, partially offset by ...

ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007

... studies have shown that THR-100 is as good or better than tPA as a thrombolytic agent for the treatment of AMI, and will be available at much lower cost, ... is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ...

The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment

... 10:356-365. (5) Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and thrombolytic Therapy. Chest. 2004; 126(suppl): 338S-400S. ...

ThromboGenics N.V.: Business Update

... programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include ...

ThromboGenics Announces Half Year Results 2008

... programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; ...
Other Contents
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous dress ... of brown evening dresses for worldwide clients. ... discounted prices, up to 50% off. , All ... are carefully made according to most fashionable styles. In ... offers pretty accessories: wedding shoes, dancing shoes, sandals, boots ...
(Date:7/13/2014)... a professional supplier of funeral products. According to the company’s ... the global market. Recently, the company has announced its latest ... offer for all the newly released items. , Despite ... made with superb materials. As is commonly noted, a nice ... the departed saint. MillionaireCasket.com is always here to help. , ...
(Date:7/13/2014)... the best treatment and variations in the quality of ... blood cancer patients still varies widely between regions within ... in European adults to date, published in The ... 5-year survival for most cancers of the blood has ... the approval of new targeted drugs in the early ...
(Date:7/13/2014)... County, NC (PRWEB) July 13, 2014 ... of its newest location, the Carolinas HealthCare System - ... facility replaces the aged Anson Community Hospital in Wadesboro. ... is approximately three miles from the previous facility. Situated ... single-story floorplan that includes an emergency room drop-off, helipad, ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
Other TagsOther Tags